Sandoz

Last week, Axios convened policy experts and advocates for a solutions-oriented roundtable discussion presented by Sandoz to discuss the ongoing generic drug shortage issues in the US, the root causes and market dynamics and potential solutions. Read more about this important conversation here: https://lnkd.in/gHGXnCNt #Generics #DrugShortages

At last month’s #REPharma24 in Barcelona, pharmaphorum’s Eloise McLennan sat down with Peter Stenico, global head of biosimilars and country president for #Sandoz Austria, to talk about the crucial role of #biosimilars in promoting #healthequity. https://lnkd.in/eVvVx2Pa

As a newly independent company, being recognized as an employer by some of our external partners and benchmark organizations is incredibly rewarding. We have achieved: 👉 # 1 Employer by LinkedIn in Germany for our approach to personal growth 👉 Reputable Employer by MojeDelo.com & Top Employer by Top Employers Institute in Slovenia 👉 Top Employer by Top Employers Institute in Austria 👉 # 1 employer in Pharma by Great Place To Work Spain and Great Place to Work® Portugal 👉 Great Place to Work for Women by Great Place To Work® Australia New Zealand Pty Ltd We recognize everything we deliver for patients is driven by our remarkable colleagues, which is why we will continue to invest in them, their personal growth, flexible working, benefits, and wellbeing. Join the team: sandoz.com/careers #SandozLife #Careers #PharmaJobs

Today marks another milestone as I reflect on the pleasure of hosting the first Sandoz Annual General Meeting. I am humbled by the vote of confidence from our shareholders, who approved all proposals put forward by the Board of Directors. I want to express my deepest gratitude to all Sandoz shareholders for embarking on this journey with us. A high turnout of shareholders attending in person, as well as voting via the independent proxy, is another testament to the brand's entrenchment in Switzerland and the emotional connection our shareholders have with it. We are very proud of what has been achieved so far and we are excited about the potential for our continued success in the future. These achievements would not have been attained without the individual and collective contributions of all our colleagues at Sandoz. I would like to wholeheartedly thank them all: Merci beaucoup! As always, I emphasize our commitment to open and continuous dialogue with all our shareholders and stakeholders. Together, we will navigate the challenges of today's ever-evolving global landscape and we will deliver on our Purpose to pioneer access for patients, as well as on our Vision to become the world’s leading and most valued biosimilars and generics company.

The #CriticalMedicinesAlliance was launched this week in Brussels, signalling a concerted effort to tackle shortages of critical medicines. The EU Commission, together with the Belgian Presidency of the EU Council, is taking a multi-stakeholder approach to solve the problem. It's time to "just do it" - to implement concrete actions. As the leading generics and biosimilars company in Europe, Sandoz is committed to contributing meaningfully to the work of the newly established Alliance. #healthcare #medicine #EUCommission #Sandoz

We're proud to celebrate a significant milestone at Sandoz: the foundation stone laying of our upcoming state-of-the-art #Biosimilar Development Center in #Ljubljana, #Slovenia. This event marks a significant stride in our mission to pioneer access for patients, This new center builds upon the solid foundation of our cutting-edge small molecule development center, reaffirming our commitment to expand access to high quality biosimilars and generic medicines globally. We extend our deepest appreciation to our colleagues, whose dedication and expertise are the driving forces behind our achievements. We also express our sincere gratitude to the distinguished guests who joined us, including the Prime Minister of Slovenia, Dr. Robert Golob; European Commissioner for Internal Market, Thierry Breton; Minister of Economy, Tourism and Sport, Matjaž Han; Swiss Ambassador to Slovenia, Gabriele Schreier; Slovenian Ambassador to Switzerland, Iztok Grmek; and Mayor of Ljubljana, Zoran Janković whose support is invaluable in our shared goal of advancing healthcare. #Generics #Biosimilars #PioneeringAccess #HealthcareLeadership 

Announcing some big wins for Sandoz! 🌟   This week the efforts of the Sandoz Corporate Affairs function was recognized not once but twice, at the PRWeek UK Corporate Affairs Awards and the PRovoke Media SABRE Awards EMEA 2024: 🏆 #PRWeekCorporateAffairsAwards Best Handling of an IPO – recognizing all the external and internal communications that supported the successful listing of Sandoz in 2023. As the judging panel commented, the work was “a great example of corporate affairs creating value." 🏆 #SABREAwardsEMEA Best Executive Communications – an award that underscores the pivotal role of senior leaders in successfully communicating major corporate milestones. As well as this, our pre-listing internal communications campaign was shortlisted for the SABRE Award in the Pharmaceutical sector. We are incredibly proud of all the Sandoz Corporate Affairs teams and practitioners across the world – and the fantastic support they provided on the Sandoz journey to independence. It’s great to receive such recognition. #SandozLife 

While Europe has been the first region to approve and adapt biosimilars, there is still more to be accomplished to democratize access to biologic medicines across the continent. Medicines for Europe’s annual BIOS24 meeting plays a key role in bringing stakeholders who can make a difference together. We believe advancements can be made to:  👉Tailor the clinical development of biosimilars   👉Improve biosimilar guidelines and approval processes  👉Implement sustainable procurement processes that increase competition and secure supply These changes would help keep biosimilars sustainable, which will benefit healthcare systems by providing more affordable treatment options, generating cost savings, and most importantly, granting greater access for patients.    Read more from our experts Isabell Remus, Chair of the Biosimilar medicines sector group at Medicines for Europe & Head Commercial Europe, Sandoz and Martin Schiestl, Global Head Regulatory Affairs Policy, Sandoz.👇 #BIOS24 #Biosimilars #Healthcare https://bit.ly/3JcxZRR

In another important step on our sustainability journey, we are excited to be joining the Energize Program as a sponsor. This industry-wide initiative aims to accelerate renewable energy adoption and enable bold climate action within pharmaceutical supply chains. https://lnkd.in/dzcw9SWe #Sustainability #ClimateAction

Today is the opening of Medicines for Europe’s 20th BIOS24, which brings together key stakeholders across healthcare to advance biosimilar adoption and increase access to life-changing medicines.👏    We have witnessed first-hand how biosimilars can deliver on their promise to expand affordable patient access to biologics while contributing to healthcare system sustainability.     To fully realize the potential from biosimilars and create opportunities for better patient outcomes, we must continue to collaborate to drive regulatory efficiency, smarter tender design, and benefit-sharing schemes that support faster biosimilar market entry.     Follow us to hear the latest updates from this exciting event!     #BIOS24 #PatientAccess #Biosimilars